

Javier P Gisbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8181711/publications.pdf>

Version: 2024-02-01

449
papers

28,071
citations

4942

84
h-index

8138

148
g-index

526
all docs

526
docs citations

526
times ranked

16684
citing authors

#	ARTICLE	IF	CITATIONS
1	Reglas y consejos para ser un buen revisor por pares de manuscritos científicos. Gastroenterología Y Hepatología, 2023, 46, 215-235.	0.2	5
2	Room for Improvement in the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2022, 56, e98-e108.	1.1	36
3	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1671-1686.e16.	2.4	15
4	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	0.6	120
5	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	0.6	288
6	Hallmarks of the human intestinal microbiome on liver maturation and function. Journal of Hepatology, 2022, 76, 694-725.	1.8	12
7	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 118-127.	3.7	49
8	Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study. European Journal of Gastroenterology and Hepatology, 2022, 34, 389-397.	0.8	13
9	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 2022, 11, 421.	1.0	8
10	Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey. Journal of Crohn's and Colitis, 2022, 16, 1070-1078.	0.6	9
11	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. Frontiers in Medicine, 2022, 9, 823900.	1.2	4
12	Inhibition of integrin $\alpha 6 \beta 1$ sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. , 2022, 10, e003465.		15
13	Evaluation of Natural Language Processing for the Identification of Crohn Disease-Related Variables in Spanish Electronic Health Records: A Validation Study for the PREMONITION-CD Project. JMIR Medical Informatics, 2022, 10, e30345.	1.3	8
14	Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study. Inflammatory Bowel Diseases, 2022, 28, 1725-1736.	0.9	27
15	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). Journal of Clinical Medicine, 2022, 11, 1658.	1.0	13
16	Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]. Journal of Crohn's and Colitis, 2022, 16, 1428-1435.	0.6	5
17	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 940-945.	0.6	5
18	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	2.4	15

#	ARTICLE	IF	CITATIONS
19	Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM): a multidisciplinary perspective. Expert Opinion on Biological Therapy, 2022, 22, 109-121.	1.4	7
20	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. Biomedicines, 2022, 10, 727.	1.4	4
21	Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg). Journal of Clinical Medicine, 2022, 11, 3544.	1.0	7
22	Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. Journal of Clinical Medicine, 2022, 11, 3915.	1.0	2
23	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology, 2021, 19, 1180-1188.e4.	2.4	12
24	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, 15, 35-42.	0.6	57
25	European Registry on <i>Helicobacter pylori</i> management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterology Journal, 2021, 9, 38-46.	1.6	39
26	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. Gut, 2021, 70, 40-54.	6.1	139
27	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. Journal of Clinical Investigation, 2021, 131, .	3.9	16
28	Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1184-1200.	0.9	5
29	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 3076.	1.8	35
30	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, 15, 1846-1851.	0.6	39
31	Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms, 2021, 9, 977.	1.6	83
32	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. Scandinavian Journal of Gastroenterology, 2021, 56, 806-811.	0.6	1
33	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology, 2021, 116, 1220-1229.	0.2	40
34	DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn's Disease patients: Results from the IBDomics study. Journal of Crohn's and Colitis, 2021, 15, S057-S058.	0.6	0
35	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 2132.	1.0	11
36	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. Molecular Nutrition and Food Research, 2021, 65, e2001034.	1.5	11

#	ARTICLE	IF	CITATIONS
37	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1277-1288.	1.9	16
38	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
39	Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2885.	1.0	38
40	Editorial: withdrawal of anti-TNFalpha—are we ready for biological therapy cycling? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 86-87.	1.9	0
41	Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions. <i>Cancers</i> , 2021, 13, 2760.	1.7	4
42	Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). <i>Medicina (Lithuania)</i> , 2021, 57, 642.	0.8	1
43	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021, 9, 766-772.	1.6	22
44	Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1041-1051.	1.9	6
45	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 495-507.e4.	0.6	89
46	The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). <i>Antibiotics</i> , 2021, 10, 965.	1.5	6
47	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021, 29, 1573-1588.e7.	5.1	71
48	Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. <i>Antibiotics</i> , 2021, 10, 1028.	1.5	5
49	Challenges of independent clinical research. <i>Gastroenterology Y Hepatología (English Edition)</i> , 2021, 44, 599-599.	0.0	0
50	Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). <i>Antibiotics</i> , 2021, 10, 1058.	1.5	48
51	Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10224.	1.8	13
52	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , 2021, 10, 4402.	1.0	10
53	Retos y desafíos de la investigación científica independiente. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 599-610.	0.2	5
54	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112239.	2.5	9

#	ARTICLE	IF	CITATIONS
55	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therapeutic Advances in Gastroenterology, 2021, 14, 17562848211018097.	1.4	11
56	European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics, 2021, 10, 13.	1.5	12
57	Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring. Nutrients, 2021, 13, 98.	1.7	14
58	Rifabutin for the Treatment of Helicobacter pylori Infection: A Review. Pathogens, 2021, 10, 15.	1.2	38
59	Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg). Annals of Gastroenterology, 2021, 35, 42-47.	0.4	3
60	V Spanish Consensus Conference on Helicobacter pylori infection treatment. GastroenterologÃa Y HepatologÃa (English Edition), 2021, , .	0.0	0
61	How to prepare a research proposal in the health sciences. GastroenterologÃa Y HepatologÃa (English) Tj ETQq1 1 0,784314 0,0 BT /Over	0,0	0
62	Ausencia de interferencia de almagato en los resultados de la prueba de aliento para el diagnÃstico de Helicobacter pylori (estudio Almatest). GastroenterologÃa Y HepatologÃa, 2021, 44, 628-636.	0.2	0
63	Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 671-671.	0.0	0
64	Ãmo elaborar un proyecto de investigaciÃn en ciencias de la salud?. GastroenterologÃa Y HepatologÃa, 2021, 44, 730-740.	0.2	2
65	CaracterÃsticas epidemiolÃgicas, clÃnicas y respuesta al tratamiento en 113 pacientes con colitis microscÃpica. GastroenterologÃa Y HepatologÃa, 2021, 44, 671-679.	0.2	1
66	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1,0	28
67	Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review. Pharmaceuticals, 2021, 14, 1190.	1.7	25
68	Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID). European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, e837-e842.	0.8	1
69	European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in Israel. Israel Medical Association Journal, 2021, 23, 38-42.	0.1	2
70	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, , .	0.6	6
71	Effectiveness and safety of methotrexate monotherapy in patients with Crohnâ€™s disease refractory to antiâ€™TNFâ€™: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2021, 53, 1021-1029.	1.9	8
72	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases, 2020, 26, 606-616.	0.9	29

#	ARTICLE	IF	CITATIONS
73	The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 557-566.	0.6	20
74	Combination of Bismuth and Standard Triple Therapy Eradicates <i>Helicobacter pylori</i> Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 89-98.	2.4	62
75	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
76	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
77	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento tópico en la colitis ulcerosa. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 97-105.	0.2	1
78	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 694-709.	0.6	148
79	Review "Treatment of <i>Helicobacter pylori</i> infection 2020. <i>Helicobacter</i> , 2020, 25, e12743.	1.6	34
80	P040 Proteomic characterisation of serum extracellular vesicles in patients with inflammatory bowel diseases: a novel approach for biomarker discovery. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S152-S153.	0.6	0
81	P086 Identification of constitutive modifications in plasma cells and B lymphocytes in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S177-S178.	0.6	0
82	P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S416-S418.	0.6	0
83	Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for <i>Helicobacter pylori</i> infection: Spanish data of the European <i>Helicobacter pylori</i> Registry (HpEuReg). <i>Helicobacter</i> , 2020, 25, e12722.	1.6	17
84	Surgery for Crohn's disease during pregnancy: a difficult decision. <i>United European Gastroenterology Journal</i> , 2020, 8, 633-634.	1.6	2
85	El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes) Tj ETQq1 1 0.784314 rgBT /Overlook <i>Hepatología</i> , 2020, 43, 551-558.	0.2	33
86	Empirical or susceptibility-guided treatment for <i>Helicobacter pylori</i> infection? A comprehensive review. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096873.	1.4	58
87	Reglas y consejos para ser un investigador de Éxito. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 540-550.	0.2	10
88	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 79-86.	0.0	0
89	Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 1056-1066.	1.6	23
90	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1062-1066.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Errores en la atención de los pacientes con enfermedad inflamatoria intestinal: estudio «ERRATA». Gastroenterología Y Hepatología, 2020, 43, 233-239.	0.2	2
92	Helicobacter pylori eradication rates in Slovenia in the period from 2017 to 2019 – data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Digestive Diseases, 2020, 39, 318-324.	0.8	5
93	Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules, 2020, 25, 5084.	1.7	12
94	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Gastroenterología Y Hepatología, 2020, 43, 117-125.	0.2	6
95	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. Journal of Clinical Medicine, 2020, 9, 3533.	1.0	29
96	A quick flow cytometry protocol to assess Helicobacter pylori viability. Journal of Microbiological Methods, 2020, 177, 106043.	0.7	5
97	P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis. Journal of Crohn's and Colitis, 2020, 14, S482-S483.	0.6	0
98	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2080-2087.	1.4	11
99	Errors in the care of inflammatory bowel disease patients: «Errata» Study. Gastroenterología Y Hepatología (English Edition), 2020, 43, 233-239.	0.0	1
100	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Gastroenterología Y Hepatología (English Edition), 2020, 43, 117-125.	0.0	0
101	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 588-596.	0.8	6
102	Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. Drugs, 2020, 80, 1085-1100.	4.9	54
103	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 870-879.	1.9	12
104	Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H. pylori management (Hp-EuReg). Helicobacter, 2020, 25, e12686.	1.6	27
105	Endothelial α 1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. EMBO Molecular Medicine, 2020, 12, e10862.	3.3	33
106	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. Gastroenterología Y Hepatología, 2020, 43, 649-658.	0.2	7
107	P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide Epidemiology study of GETECCU. Journal of Crohn's and Colitis, 2020, 14, S594-S597.	0.6	7
108	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. Journal of Crohn's and Colitis, 2020, 14, 1037-1048.	0.6	55

#	ARTICLE	IF	CITATIONS
109	Empirical or susceptibility-guided treatment of refractory <i>Helicobacter pylori</i> infection?. <i>GastroHep</i> , 2020, 2, 4-5.	0.3	1
110	Systematic review: gastric microbiota in health and disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 582-602.	1.9	113
111	P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S359-S360.	0.6	0
112	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1290-1298.	0.6	5
113	<i>Helicobacter pylori</i> "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain" Results of the Hp-Breath initiative. <i>Helicobacter</i> , 2020, 25, e12693.	1.6	25
114	Derrame pericárdico asociado al tratamiento con mesalazina en un paciente con colitis ulcerosa. <i>Gastroenterología Y Hepatología</i> , 2020, 44, 721-723.	0.2	1
115	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1802-1811.	0.2	12
116	Eradication of <i>Helicobacter pylori</i> Infection with Non-Bismuth Quadruple Concomitant Therapy. <i>Frontiers in Anti-infective Drug Discovery</i> , 2020, , 1-34.	0.6	5
117	P128 Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real life experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S201-S201.	0.6	0
118	Encuesta de adherencia al tratamiento en enfermedad inflamatoria intestinal. Estudio ENADEII. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 285-292.	0.2	3
119	Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit. <i>Revista Española De Enfermedades Digestivas</i> , 2020, 112, 688-693.	0.1	1
120	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 79-86.	0.2	0
121	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory) Tj ETQq1 1 0.784314 rgBT /Ove (English Edition), 2020, 43, 551-558.	0.0	7
122	Alertas sobre la seguridad de las quinolonas: ¿debemos modificar su prescripción en el tratamiento de la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología Y Hepatología</i> , 2019, 42, 461-463.	0.2	3
123	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg). <i>Helicobacter</i> , 2019, 24, e12630.	1.6	46
124	Efficacy of tofacitinib treatment in ulcerative colitis. <i>Gastroenterología Y Hepatología (English)</i> Tj ETQq0 0 0 rgBT /Ove lock_10 Tf 50 1. 0.0	0.0	3
125	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiología, diagnóstico y pronóstico. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 568-578.	0.2	11
126	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 2605.	1.7	26

#	ARTICLE	IF	CITATIONS
127	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S328-S329.	0.6	0
128	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. <i>EBioMedicine</i> , 2019, 48, 648-655.	2.7	72
129	Review: Treatment of <i>Helicobacter pylori</i> Infection 2019. <i>Helicobacter</i> , 2019, 24, e12640.	1.6	38
130	P138 Prediction model to safely cease anti-TNF therapy in Crohn's disease: individual patient data meta-analysis (IPD-MA). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S158-S159.	0.6	1
131	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2460-2463.	1.1	12
132	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 780-788.	1.9	40
133	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986784.	1.4	1
134	Warnings on the safety of quinolones: Should <i>Helicobacter pylori</i> treatment prescriptions be modified?. <i>Gastroenterology and Hepatology (English Edition)</i> , 2019, 42, 461-463.	0.0	0
135	DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S052-S053.	0.6	0
136	P526 Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S376-S376.	0.6	0
137	Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity. <i>Immunity</i> , 2019, 50, 446-461.e9.	6.6	143
138	Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 996-1002.	0.6	52
139	Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 258-268.	1.9	13
140	Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 278-288.	1.9	53
141	A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection. <i>United European Gastroenterology Journal</i> , 2019, 7, 1051-1063.	1.6	35
142	EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984703.	1.4	18
143	Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1380-1386.	0.6	19
144	Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , 2019, 24, e12593.	1.6	18

#	ARTICLE	IF	CITATIONS
145	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1492-1500.	0.6	37
146	Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. <i>Gastroenterolog�a Y Hepatolog�a</i> , 2019, 42, 403-412.	0.2	20
147	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn�s disease. <i>Pharmacogenomics Journal</i> , 2019, 19, 547-555.	0.9	4
148	P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn�s disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S529-S531.	0.6	0
149	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. <i>Gastroenterolog�a Y Hepatolog�a (English Edition)</i> , 2019, 42, 90-101.	0.0	2
150	Role of food proteins and bioactive peptides in inflammatory bowel disease. <i>Trends in Food Science and Technology</i> , 2019, 88, 194-206.	7.8	55
151	P223 Efficacy and safety of tacrolimus in Crohn�s disease: a nationwide, multi-centric study from GETECCU. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S207-S208.	0.6	0
152	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S321-S322.	0.6	1
153	Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn�s patients: Results of the APPRECIATE trial. <i>Digestive and Liver Disease</i> , 2019, 51, 529-535.	0.4	3
154	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019, 37, 266-283.	0.8	63
155	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatolog�a Cl�nica</i> , 2019, 15, 63-68.	0.2	1
156	Meta�analysis of three�one single capsule bismuth�containing quadruple therapy for the eradication of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2019, 24, e12570.	1.6	57
157	P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S410-S410.	0.6	0
158	P013 Novel immunomodulatory role of food bioactive peptide lunasin in the healthy human intestinal mucosa. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S092-S093.	0.6	0
159	Empirical <i>Helicobacter pylori</i> rescue therapy: an 18�year single-centre study of 1200 patients. <i>GastroHep</i> , 2019, 1, 311-324.	0.3	12
160	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2822-2823.	2.4	1
161	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987420.	1.4	5
162	Response to the Letter to the Editor: �Response to Infliximab After Loss of Response to Adalimumab in Crohn�s Disease�. <i>Inflammatory Bowel Diseases</i> , 2019, 26, e6.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis?. United European Gastroenterology Journal, 2019, 7, 997-998.	1.6	0
164	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. Inflammatory Intestinal Diseases, 2019, 4, 161-174.	0.8	6
165	Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy. Alimentary Pharmacology and Therapeutics, 2019, 49, 242-250.	1.9	23
166	Quality of Care™ Standards in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis, 2019, 13, 127-137.	0.6	43
167	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences, 2019, 64, 846-854.	1.1	24
168	Manejo de la colitis ulcerosa aguda grave en España: Resultados de una encuesta sobre práctica clínica. Gastroenterología Y Hepatología, 2019, 42, 90-101.	0.2	9
169	Differences between childhood and adulthood onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Alimentary Pharmacology and Therapeutics, 2019, 49, 419-428.	1.9	28
170	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. Journal of Functional Foods, 2019, 52, 459-468.	1.6	9
171	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. Journal of Crohn's and Colitis, 2019, 13, 374-384.	0.6	36
172	Long-Term Safety of In Utero Exposure to Anti-TNF± Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. American Journal of Gastroenterology, 2018, 113, 396-403.	0.2	134
173	P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU. Journal of Crohn's and Colitis, 2018, 12, S174-S176.	0.6	0
174	Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. Gastroenterología Y Hepatología (English Edition), 2018, 41, 272-280.	0.0	2
175	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterología Y Hepatología (English) Tj ETQq1 1 0.784314 rgBT /Ove	0.2	34
176	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal. Gastroenterología Y Hepatología, 2018, 41, 205-221.	0.2	34
177	Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología Y Hepatología, 2018, 41, 272-280.	0.2	11
178	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Alimentary Pharmacology and Therapeutics, 2018, 47, 605-614.	1.9	57
179	Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. Molecular Nutrition and Food Research, 2018, 62, e1700931.	1.5	35
180	Validation of the United Registries for Clinical Assessment and Research™ [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	0.6	8

#	ARTICLE	IF	CITATIONS
181	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 353-359.	0.4	28
182	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 118-127.	0.2	26
183	<i>Helicobacter Pylori</i> Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 972-979.	0.2	52
184	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Gut</i> , 2018, 67, 237-243.	6.1	119
185	Preguntas y errores en el diagnóstico y manejo de la anemia en pacientes con hemorragia digestiva. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 63-76.	0.2	6
186	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 17-31.	0.6	151
187	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 63-76.	0.0	5
188	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 839-851.	1.9	71
189	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 514-529.	0.0	2
190	Treatment of <i>Helicobacter pylori</i> infection in 2018. <i>Helicobacter</i> , 2018, 23, e12519.	1.6	46
191	Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of <i>MUC2</i> variants with the evolution of the lesions and identifies a significant association with <i>NFKB1</i> and <i>CD14</i> . <i>International Journal of Cancer</i> , 2018, 143, 2777-2786.	2.3	9
192	The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1649-1659.	0.9	42
193	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 389-405.	0.2	21
194	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 389-405.	0.0	2
195	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 514-529.	0.2	33
196	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1270-1279.	0.6	15
197	Acute severe ulcerative colitis: State of the art treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 59-69.	1.0	28
198	Human intestinal pro-inflammatory CD11c ^{high} CCR2 ⁺ CX3CR1 ⁺ macrophages, but not their tolerogenic CD11c ^{low} CCR2 ⁺ CX3CR1 ⁺ counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 1114-1126.	2.7	105

#	ARTICLE	IF	CITATIONS
199	Probiotic supplementation with <i>Lactobacillus plantarum</i> and <i>Pediococcus acidilactici</i> for <i>Helicobacter pylori</i> therapy: A randomized, double-blind, placebo-controlled trial. <i>Helicobacter</i> , 2018, 23, e12529.	1.6	34
200	Evropeyskiy registr <i>Helicobacter pylori</i> (Hp-EuReg): analiz dannyykh 2360 bol'nykh, poluchavshikh terapiyu pervoy linii v Rossii. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 35-42.	0.2	9
201	La relaci3n mentor-aprendiz en medicina. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2017, 40, 48-57.	0.2	14
202	Tratamiento actual de la infecci3n por <i>Helicobacter pylori</i> . <i>Medicina Cl3nica</i> , 2017, 148, 20-22.	0.3	6
203	Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 855-856.	1.9	2
204	Current treatment of <i>Helicobacter pylori</i> infection. <i>Medicina Cl3nica (English Edition)</i> , 2017, 148, 20-22.	0.1	1
205	Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1374-1375.	1.9	3
206	Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment. <i>Digestive and Liver Disease</i> , 2017, 49, 973-977.	0.4	15
207	Optimization strategies aimed to increase the efficacy of <i>H. Pylori</i> eradication therapies. <i>Helicobacter</i> , 2017, 22, e12392.	1.6	69
208	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , 2017, 112, 1135-1143.	0.2	27
209	Reply. <i>Gastroenterology</i> , 2017, 152, 303-304.	0.6	2
210	Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for <i>Helicobacter pylori</i> Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 765-776.	4.9	23
211	Management of <i>Helicobacter pylori</i> infection—the Maastricht V/Florence Consensus Report. <i>Gut</i> , 2017, 66, 6-30.	6.1	2,245
212	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 481-490.	1.1	43
213	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 120-131.	0.2	93
214	Enfermedad cel3aca no respondedora: crisis cel3aca vs. enfermedad cel3aca refractaria con respuesta a corticoides. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2017, 40, 529-530.	0.2	2
215	Accuracy of the Ultra-Rapid Urease Test for diagnosis of <i>Helicobacter pylori</i> infection. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2017, 40, 651-657.	0.2	15
216	Letter: the definition of budesonide dependence in microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 635-635.	1.9	3

#	ARTICLE	IF	CITATIONS
217	Ustekinumab en el tratamiento de la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 688-698.	0.2	13
218	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2017, 49, 1086-1091.	0.4	23
219	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER ^β /ER ^α) Indicates Endoscopic Activity in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2744-2754.	1.1	22
220	Treatment of <i>Helicobacter pylori</i> infection 2017. <i>Helicobacter</i> , 2017, 22, e12410.	1.6	26
221	Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for <i>Helicobacter pylori</i> infection. <i>International Journal of Clinical Practice</i> , 2017, 71, e13004.	0.8	9
222	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 472-483.	0.2	27
223	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1430-1439.	0.6	123
224	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Hepatología</i> , 2017, 40, 658-662.	0.2	11
225	Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. <i>American Journal of Gastroenterology</i> , 2017, 112, 1761-1764.	0.2	16
226	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1394-1402.	0.9	71
227	Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. <i>Biomarkers</i> , 2017, 22, 133-144.	0.9	21
228	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 688-698.	0.0	4
229	<i>Helicobacter pylori</i> treatment results in Slovenia in the period 2013-2015 as a part of European Registry on <i>Helicobacter pylori</i> Management. <i>Radiology and Oncology</i> , 2017, 52, 1-6.	0.6	9
230	Accuracy of the Ultra-Rapid Urease Test for diagnosis of <i>Helicobacter pylori</i> infection. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 651-657.	0.0	1
231	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 <i>Hepatología (English Edition)</i> , 2017, 40, 658-662.	0.0	0
232	Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer. <i>PLoS ONE</i> , 2017, 12, e0176043.	1.1	21
233	Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 583-598.	0.9	2
234	Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 400-426.	1.9	54

#	ARTICLE	IF	CITATIONS
235	Monitoring thiopurine metabolites in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2016, 7, 301-307.	0.9	22
236	IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología</i> (English Edition), 2016, 39, 697-721.	0.0	27
237	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016, 122, 33-41.	2.0	12
238	In <i>H. pylori</i> -infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. <i>Evidence-Based Medicine</i> , 2016, 21, 144-144.	0.6	1
239	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterología Y Hepatología</i> (English Edition), 2016, 39, 677-686.	0.0	2
240	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1020-1020.	1.9	0
241	Últimas novedades presentadas en gastroenterología. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 1-2.	0.2	1
242	Enfermedades relacionadas con la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología Y Hepatología</i> , 2016, 39, 36-46.	0.2	5
243	Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 677-686.	0.2	7
244	The Toronto Consensus for the Treatment of <i>Helicobacter pylori</i> Infection in Adults. <i>Gastroenterology</i> , 2016, 151, 51-69.e14.	0.6	671
245	IV Conferencia Española de Consenso sobre el tratamiento de la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología Y Hepatología</i> , 2016, 39, 697-721.	0.2	97
246	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	2.3	97
247	Letter: <i>Helicobacter pylori</i> infection and eosinophilic oesophagitis - causal or casual inverse association?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1244-1244.	1.9	2
248	<i>Propionibacterium acnes</i> overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis. <i>Journal of Pathology</i> , 2016, 240, 425-436.	2.1	42
249	Treatment of <i>Helicobacter pylori</i> infection 2016. <i>Helicobacter</i> , 2016, 21, 55-61.	1.6	10
250	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034.	1.5	35
251	Towards effective empirical treatment for <i>Helicobacter pylori</i> eradication. <i>Lancet</i> , The, 2016, 388, 2325-2326.	6.3	4
252	Letter: anti-TNF in steroid-dependent ulcerative colitis - are the available data enough?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 102-102.	1.9	0

#	ARTICLE	IF	CITATIONS
253	Letter: oral low-dose methotrexate for collagenous colitis – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 98-98.	1.9	0
254	Ustekinumab for the Treatment of Refractory Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1662-1669.	0.9	146
255	Ensuring the highest eradication rates in <i>H. pylori</i> : the case of non-bismuth quadruple concomitant therapy. <i>European Journal of Internal Medicine</i> , 2016, 33, 1-2.	1.0	0
256	Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for <i>Helicobacter pylori</i> first-line treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2740-2753.	1.3	36
257	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1339-1349.	0.9	20
258	Systematic review: third-line susceptibility-guided treatment for <i>Helicobacter pylori</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 437-448.	1.4	35
259	Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for) <i>Tj ETQq1 1</i> 0.784314 rgBT /Overl 229-235.	1.6	7
260	Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 953-958.	1.4	87
261	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 261-268.	0.2	42
262	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. <i>Digestive and Liver Disease</i> , 2016, 48, 601-607.	0.4	32
263	Effectiveness of anti-TNF± drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF± agent. <i>Digestive and Liver Disease</i> , 2016, 48, 613-619.	0.4	13
264	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 657-662.	0.6	25
265	Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 168-169.	1.9	1
266	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2016, 111, 632-647.	0.2	156
267	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, 592-600.	0.4	37
268	Outcome after a dose –de-intensification strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterology & Hepatology</i> , 2016, 39, 255-260.	0.2	8
269	European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg protocol): The first results of Russian Centers. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2016, 5, 9.	0.3	1
270	Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1221-1222.	1.9	1

#	ARTICLE	IF	CITATIONS
271	Letter: clarithromycin dose for <i>H. Pylori</i> therapy remains unresolved. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 631-632.	1.9	1
272	Letter: sitafloxacin for <i>H. Pylori</i> infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 942-943.	1.9	1
273	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 940-941.	1.9	2
274	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 391-405.	1.9	99
275	Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates. <i>Frontiers in Immunology</i> , 2015, 6, 512.	2.2	145
276	Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	1.4	16
277	Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 2260-2262.	1.4	12
278	Rectal hypersensitivity in patients with quiescent ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 592-592.	0.6	7
279	Treatment of <i>Helicobacter pylori</i> Infection 2015. <i>Helicobacter</i> , 2015, 20, 54-61.	1.6	34
280	Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study. <i>Gastroenterology</i> , 2015, 148, 794-805.	0.6	46
281	Is Less More: Does Leukopenia Predict Remission in Patients with Inflammatory Bowel Disease Receiving Thiopurine Treatment?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 4-6.	1.1	2
282	Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015, 47, 108-113.	0.4	22
283	Optimised empiric triple and concomitant therapy for <i>Helicobacter pylori</i> eradication in clinical practice: the OPRICON study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 581-589.	1.9	70
284	<i>Helicobacter Pylori</i> First-Line and Rescue Treatments in the Presence of Penicillin Allergy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 458-464.	1.1	42
285	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 379-386.	0.6	21
286	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 613-623.	1.9	266
287	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	0.6	425
288	Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for <i>Helicobacter pylori</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2447-2455.	1.3	120

#	ARTICLE	IF	CITATIONS
289	Editorial: quadruple therapy for <i>H. pylori</i> eradication is better than triple therapy – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 695-696.	1.9	0
290	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 768-775.	1.9	91
291	Effectiveness of Adalimumab in Perianal Fistulas in Crohn's Disease Patients Naive to Anti-TNF Therapy. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 34-40.	1.1	59
292	Response to. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 105-106.	0.8	1
293	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1063-1070.	0.6	45
294	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3075-3084.	1.1	26
295	The association between <i>Helicobacter pylori</i> infection and inflammatory bowel disease based on meta-analysis. <i>United European Gastroenterology Journal</i> , 2015, 3, 539-550.	1.6	76
296	Letter: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 494-495.	1.9	1
297	Letter: tumour necrosis factor alpha blocker switching - a not so simple pharmacokinetic. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1302-1303.	1.9	0
298	Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 847-858.e4.	2.4	322
299	Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease. <i>Current Drug Metabolism</i> , 2015, 15, 875-881.	0.7	3
300	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11273.	1.4	46
301	Optimizing clarithromycin-containing therapy for <i>Helicobacter pylori</i> in the era of antibiotic resistance. <i>World Journal of Gastroenterology</i> , 2014, 20, 10338.	1.4	59
302	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 645-659.	1.9	219
303	Letter: acute severe ulcerative colitis - should all patients be treated equally?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 113-113.	1.9	1
304	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 459-477.	1.9	129
305	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 941-948.	0.8	54
306	Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 240-251.	0.6	89

#	ARTICLE	IF	CITATIONS
307	Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1287-1293.	0.6	24
308	Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for <i>H. pylori</i> Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 383-389.	1.1	48
309	Randomised clinical trial comparing sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication in routine clinical practice. <i>Gut</i> , 2014, 63, 244-249.	6.1	119
310	Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. <i>Human Immunology</i> , 2014, 75, 71-75.	1.2	45
311	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1529-1538.	0.6	45
312	How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1749-1762.	1.0	11
313	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014, 23, 6927-6934.	1.4	39
314	Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 183-190.	0.6	32
315	Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 654-661.	0.6	20
316	Optimum second-line regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2014, , .	1.5	1
317	Optimized Nonbismuth Quadruple Therapies Cure Most Patients With <i>Helicobacter pylori</i> Infection in Populations With High Rates of Antibiotic Resistance. <i>Gastroenterology</i> , 2013, 145, 121-128.e1.	0.6	177
318	Health Care Costs of Complex Perianal Fistula in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3400-3406.	1.1	38
319	Current Management of Iron Deficiency Anemia in Inflammatory Bowel Diseases: A Practical Guide. <i>Drugs</i> , 2013, 73, 1761-1770.	4.9	35
320	Treatment of <i>Helicobacter pylori</i> Infection 2013. <i>Helicobacter</i> , 2013, 18, 58-65.	1.6	52
321	<i>Helicobacter pylori</i> inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , 2013, 68, 284-290.	2.6	17
322	Letter: mucosal healing in ulcerative colitis " higher relevance than in Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 207-207.	1.9	1
323	Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 992-992.	1.9	1
324	Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 717-722.	0.6	80

#	ARTICLE	IF	CITATIONS
325	Therapeutic guidelines on ulcerative colitis: A GRADE methodology based effort of GETECCU. <i>GastroenterologÅa Y HepatologÅa</i> , 2013, 36, 104-114.	0.2	44
326	Reply to Dr. Katsanos et al.'s letter. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e23-e24.	0.6	0
327	Safety of Thiopurines and Anti-TNF-Î± Drugs During Pregnancy in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, 433-440.	0.2	197
328	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter</i>) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.9	73
329	Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. <i>International Journal of Cancer</i> , 2013, 133, 1023-1032.	2.3	90
330	Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, 1426-1438.	0.2	105
331	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple sequential or concomitant treatment to eradicate <i>H. pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 652-656.	0.6	32
332	Letter: infliximab in severe ulcerative colitis â€“ is it useful for all patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1413-1413.	1.9	1
333	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 752-760.	1.9	73
334	<i>Helicobacter Pylori</i> "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. <i>Clinical and Translational Gastroenterology</i> , 2013, 4, e32.	1.3	53
335	Kinetics of Anti-Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 554-558.	0.9	38
336	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013, , CD008337.	1.5	120
337	Safety of Thiopurine Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1404-1410.	0.9	243
338	Impact of Current Smoking on the Clinical Course of Microscopic Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1470-1476.	0.9	54
339	Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 130-135.	1.1	60
340	Epidemiological risk factors in microscopic colitis: a prospective case-control study. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 411-7.	0.9	80
341	Probiotics for <i>Helicobacter pylori</i> eradication therapy: not ready for prime time. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 441-444.	0.1	16
342	Rescue Therapy for <i>Helicobacter pylori</i> Infection 2012. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-12.	0.7	34

#	ARTICLE	IF	CITATIONS
343	Treatment of <i>Helicobacter pylori</i> infection 2012. <i>Helicobacter</i> , 2012, 17, 36-42.	1.6	37
344	Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 812-812.	1.9	0
345	Letter: are lymphocytic colitis and collagenous colitis really the same disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 606-606.	1.9	9
346	Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible <i>Helicobacter pylori</i> and versus Sequential Therapy for Clarithromycin-Resistant Strains. <i>Helicobacter</i> , 2012, 17, 269-276.	1.6	79
347	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1909-1915.	6.3	517
348	Long-Term Follow-Up of 1,000 Patients Cured of <i>Helicobacter pylori</i> Infection Following an Episode of Peptic Ulcer Bleeding. <i>American Journal of Gastroenterology</i> , 2012, 107, 1197-1204.	0.2	64
349	Systematic review: antibodies and anti-TNF levels in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 971-986.	1.9	91
350	Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1460-1466.	0.2	121
351	Intensification of infliximab therapy in Crohn's disease: Efficacy and safety. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 62-67.	0.6	37
352	Management of <i>Helicobacter pylori</i> infection – the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012, 61, 646-664.	6.1	2,023
353	Update on non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 23.	1.0	114
354	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 685-690.	0.9	50
355	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2026-2033.	0.9	118
356	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 275-283.	1.9	102
357	Review article: rifabutin in the treatment of refractory <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 209-221.	1.9	161
358	Fourth-line rescue therapy with rifabutin in patients with three <i>Helicobacter pylori</i> eradication failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 941-947.	1.9	57
359	Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1379-1385.	1.9	77
360	Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1484-1485.	1.9	25

#	ARTICLE	IF	CITATIONS
361	High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high <i>Helicobacter pylori</i> eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 190-196.	1.9	26
362	Commentary: comparators in <i>H. pylori</i> eradication – stating the ethics of statins. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 400-401.	1.9	5
363	Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 414-425.	1.9	165
364	Effectiveness of infliximab after adalimumab failure in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 5219-24.	1.4	25
365	Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. <i>Gastroenterology y Hepatología</i> , 2011, 34, 443-448.	0.2	26
366	Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 113-118.	1.1	114
367	Is Culture Necessary before First-line Treatment for <i>Helicobacter pylori</i> Infection?. <i>Internal Medicine</i> , 2011, 50, 2717-2717.	0.3	17
368	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 340-348.	1.9	92
369	Review article: non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 604-617.	1.9	145
370	Review article: common misconceptions in the management of <i>Helicobacter pylori</i> -associated gastric MALT-lymphoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1047-1062.	1.9	59
371	Review article: the effectiveness of standard triple therapy for <i>Helicobacter pylori</i> has not changed over the last decade, but it is not good enough. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1255-1268.	1.9	114
372	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 619-633.	1.9	101
373	Has <i>H. pylori</i> Prevalence in Bleeding Peptic Ulcer Been Underestimated? A Meta-Regression. <i>American Journal of Gastroenterology</i> , 2011, 106, 398-405.	0.2	72
374	A new, single-capsule bismuth-containing quadruple therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 307-309.	8.2	26
375	Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory Bowel Disease. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 765-773.	0.9	39
376	Sequential Therapy for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 313-325.	1.1	194
377	Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 881-895.	0.9	120
378	W1300 Effectiveness of Infliximab After Adalimumab Failure in Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, S-694.	0.6	2

#	ARTICLE	IF	CITATIONS
379	Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 144-152.	0.6	139
380	Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 567-574.	0.6	29
381	<i>Helicobacter pylori</i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , 2010, 42, 287-290.	0.4	53
382	Anemia and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2009, 15, 4659.	1.4	162
383	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. <i>European Journal of General Practice</i> , 2009, 15, 154-160.	0.9	8
384	Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1485-1491.	0.9	114
385	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1190-1198.	0.9	265
386	Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 126-137.	1.9	186
387	Review article: <i>Helicobacter pylori</i> -negative duodenal ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 791-815.	1.9	108
388	Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2009, 41, 56-66.	0.4	195
389	Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 90.	1.0	59
390	Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. <i>American Journal of Gastroenterology</i> , 2009, 104, 760-767.	0.2	564
391	Management of gastro-oesophageal reflux disease in primary care: a European observational study. <i>Current Medical Research and Opinion</i> , 2009, 25, 2777-2784.	0.9	17
392	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. <i>European Journal of General Practice</i> , 2009, 15, 154-160.	0.9	12
393	Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 346-354.	1.9	77
394	Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 868-877.	1.9	110
395	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. <i>Gastroenterology & Hepatology</i> , 2008, 31, 421-426.	0.2	24
396	Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1299-1307.	0.2	191

#	ARTICLE	IF	CITATIONS
397	Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients. American Journal of Gastroenterology, 2008, 103, 71-76.	0.2	79
398	Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review. American Journal of Gastroenterology, 2008, 103, 1783-1800.	0.2	223
399	Rescue regimens after Helicobacter pylori treatment failure. World Journal of Gastroenterology, 2008, 14, 5385.	1.4	98
400	Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review. American Journal of Gastroenterology, 2007, 102, 1518-1527.	0.2	182
401	5-Aminosalicylates and renal function in inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 629-638.	0.9	186
402	Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients. Inflammatory Bowel Diseases, 2007, 13, 1106-1114.	0.9	103
403	First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2007, 26, 495-500.	1.9	49
404	Eradication of Helicobacter pylori for the Prevention of Peptic Ulcer Rebleeding. Helicobacter, 2007, 12, 279-286.	1.6	32
405	13C-urea Breath Test during Hospitalization for the Diagnosis of Helicobacter pylori Infection in Peptic Ulcer Bleeding. Helicobacter, 2007, 12, 231-237.	1.6	27
406	Evolution of Helicobacter pylori Therapy from a Meta-analytical Perspective. Helicobacter, 2007, 12, 50-58.	1.6	77
407	Thiopurine Methyltransferase Activity in Spain: A Study of 14,545 Patients. Digestive Diseases and Sciences, 2007, 52, 1262-1269.	1.1	82
408	Risk Assessment and Outpatient Management in Bleeding Peptic Ulcer. Journal of Clinical Gastroenterology, 2006, 40, 129-134.	1.1	13
409	Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary Pharmacology and Therapeutics, 2006, 23, 35-44.	1.9	296
410	Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Alimentary Pharmacology and Therapeutics, 2006, 24, 1469-1474.	1.9	81
411	Accuracy of Helicobacter pylori Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2006, 101, 848-863.	0.2	190
412	Accuracy of Monoclonal Stool Antigen Test for the Diagnosis of H. pylori Infection: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2006, 101, 1921-1930.	0.2	250
413	Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures. American Journal of Gastroenterology, 2006, 101, 243-247.	0.2	98
414	Thiopurine Methyltransferase (TPMT) Activity and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of 394 Patients. American Journal of Gastroenterology, 2006, 101, 2769-2776.	0.2	110

#	ARTICLE	IF	CITATIONS
415	Gastric MALT lymphoma: clinical characteristics and prevalence of <i>H. pylori</i> infection in a series of 37 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 655-65.	0.1	12
416	Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. <i>Hepato-Gastroenterology</i> , 2006, 53, 399-404.	0.5	8
417	<i>Helicobacter pylori</i> "Rescue" Therapy After Failure of Two Eradication Treatments. <i>Helicobacter</i> , 2005, 10, 363-372.	1.6	99
418	Meta-analysis: role of <i>Helicobacter pylori</i> eradication in the prevention of peptic ulcer in NSAID users. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1411-1418.	1.9	201
419	7-day rescue therapy with ranitidine bismuth citrate after <i>Helicobacter pylori</i> treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1249-1253.	1.9	11
420	<i>Helicobacter pylori</i> first-line treatment and rescue options in patients allergic to penicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1041-1046.	1.9	56
421	Esomeprazole-Based Therapy in <i>Helicobacter pylori</i> Eradication: Any Effect by Increasing the Dose of Esomeprazole or Prolonging the Treatment?. <i>American Journal of Gastroenterology</i> , 2005, 100, 1935-1940.	0.2	34
422	Evaluation of 3 different tests for the detection of stool antigens to confirm <i>Helicobacter pylori</i> eradication after treatment. A pilot study. <i>GastroenterologÅa Y HepatologÅa</i> , 2005, 28, 615-618.	0.2	18
423	<i>Helicobacter pylori</i> eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 617-629.	1.9	127
424	Evaluation of three different tests for the detection of stool antigens to diagnose <i>Helicobacter pylori</i> infection in patients with upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 923-929.	1.9	39
425	Review article: 13 C-urea breath test in the diagnosis of <i>Helicobacter pylori</i> infection - a critical review. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1001-1017.	1.9	305
426	The TETRA Study: A prospective evaluation of <i>Helicobacter pylori</i> 'Test-and-Treat' Strategy on 736 Patients in Clinical Practice. <i>Helicobacter</i> , 2004, 9, 28-38.	1.6	35
427	Empirical <i>Helicobacter pylori</i> "rescue" therapy after failure of two eradication treatments. <i>Digestive and Liver Disease</i> , 2004, 36, 7-12.	0.4	20
428	Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 689-692.	0.8	37
429	The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 135-138.	0.8	29
430	Pantoprazole based therapies in <i>Helicobacter pylori</i> eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 89-99.	0.8	28
431	'Rescue' Therapy with Rifabutin after Multiple <i>Helicobacter pylori</i> Treatment Failures. <i>Helicobacter</i> , 2003, 8, 90-94.	1.6	97
432	Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 17-27.	1.9	22

#	ARTICLE	IF	CITATIONS
433	Rabeprazole-based therapies in Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2003, 17, 751-764.	1.9	34
434	Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Alimentary Pharmacology and Therapeutics, 2003, 18, 543-544.	1.9	76
435	Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. Journal of Hepatology, 2003, 39, 620-627.	1.8	144
436	H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 509 , CD004062.		9
437	Attitude facing a patient suffering from Helicobacter pylori infection resistant to a triple therapy. Revista Espanola De Enfermedades Digestivas, 2003, 95, 220-8, 210-19.	0.1	1
438	Role of partner's infection in reinfection after Helicobacter pylori eradication. European Journal of Gastroenterology and Hepatology, 2002, 14, 865-871.	0.8	41
439	The Stool Antigen Test for Detection of Helicobacter pylori after Eradication Therapy. Annals of Internal Medicine, 2002, 136, 280.	2.0	104
440	Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Alimentary Pharmacology and Therapeutics, 2002, 16, 1149-1156.	1.9	112
441	Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Alimentary Pharmacology and Therapeutics, 2002, 16, 1047-1057.	1.9	190
442	A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2000, 14, 603-609.	1.9	213
443	Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Alimentary Pharmacology and Therapeutics, 2000, 14, 1319-1328.	1.9	159
444	Seven-day "rescue" therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Alimentary Pharmacology and Therapeutics, 1999, 13, 1311-1316.	1.9	78
445	Helicobacter pylori 'Test-and-Treat' Strategy for Dyspeptic Patients. Scandinavian Journal of Gastroenterology, 1999, 34, 644-652.	0.6	26
446	Prevalence of Helicobacter pylori infection in medical professionals in Spain. European Journal of Gastroenterology and Hepatology, 1999, 11, 239-242.	0.8	20
447	Helicobacter pylori and gastroesophageal reflux disease: friends or foes?. Hepato-Gastroenterology, 1999, 46, 1023-9.	0.5	14
448	Recurrence of Helicobacter pylori infection after Eradication: Incidence and Variables Influencing It. Scandinavian Journal of Gastroenterology, 1998, 33, 1144-1151.	0.6	50
449	Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Frontiers in Microbiology, 0, 13, .	1.5	27